scholarly journals The Association of Serum IL-33 and sST2 with Breast Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Zhi-Ping Yang ◽  
Dan-Yan Ling ◽  
Yong-Hong Xie ◽  
Wan-Xin Wu ◽  
Jin-Rui Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Serum Levels ◽  
The Body ◽  
Breast Cancer Dataset ◽  
Breast Cancer Patients ◽  
Interleukin 33 ◽  
Factor C

Breast cancer is one of the most common malignant diseases in women. The main cause of death from breast cancer is its metastases at distant sites in the body. Interleukin-33 (IL-33) is a cytokine of the IL-1 family and found overexpressed in various cancers. The aim of the present study was to explore the association of serum IL-33 and sST2 with breast cancer. Here, the serum levels of Interleukin-33 (IL-33) and sST2 were found significantly higher in breast cancer patients than in healthy volunteers. Serum levels of vascular endothelial growth factor (VEGF), metalloproteinase-11 (MMP-11), and platelet-derived growth factor-C (PDGF-C) were also greater in breast cancer patients compared to healthy volunteers. We found that serum levels of IL-33 or sST2 were positively correlated with the serum levels of VEGF, MMP-11, and PDGF-C. Moreover, breast cancer dataset downloaded from The Cancer Genome Atlas showed that patients with higher level of MMP-11 or PDGF-C expression had shorter survival time than those with lower level of these proteins. In conclusion, IL-33 and sST2 may serve as noninvasive diagnosis markers for breast cancer. IL-33 and sST2 were significantly associated with MMP-11 or PDGF-C which indicated poor prognosis of breast cancer patients.

Altered serum levels of insulin-like growth-factor binding proteins in breast cancer patients

1998 ◽  
Vol 5 (2) ◽  
pp. 194-201 ◽  
Author(s):  
Eng-Hen Ng ◽  
Chen-Yang Ji ◽  
Puay-Hoon Tan ◽  
Valerie Lin ◽  
Khee-Chee Soo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cancer Patients ◽  
Binding Proteins ◽  
Serum Levels ◽  
Insulin Like Growth Factor ◽  
Breast Cancer Patients ◽  
Factor Binding ◽  
Altered Serum

Association of serum levels of the growth factor GP88 with disease progression in breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22021-e22021
Author(s):  
G. Serrero ◽  
K. Tkaczuk ◽  
M. Zhan ◽  
N. Tait ◽  
C. Ilan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Serum Level ◽  
Disease Progression ◽  
Cancer Patients ◽  
Early Stage ◽  
Serum Levels ◽  
P Value ◽  
Breast Cancer Patients ◽  
Early Stage Disease

e22021 Background: The autocrine growth factor GP88 is an important player in breast cancer. GP88 is expressed in human BC tumors in correlation with their tumorigenicity. Increased GP88 expression was associated with anti-estrogen therapy resistance in ER+ cells and Herceptin resistance in Her-2 overexpressing breast tumors. Inhibition of GP88 expression inhibited tumor incidence and growth in nude mice. Immunohistochemical studies have shown that GP88 is expressed in invasive ductal carcinomas (IDC) and that high GP88 expression correlated with increased recurrence and mortality. Since GP88 is found in serum, we hypothesized that GP88 was elevated in the sera of breast cancer patients compared to healthy individuals and that GP88 serum level increases with disease progression. Methods: An IRB approved prospective study was established at the University of Maryland Breast Clinic to determine the serum level of GP88 in breast cancer patients (BC pts). Approximately 5 ml of blood was drawn every three months. GP88 serum concentration was determined in triplicate by human GP88 enzyme immunoassay. 190 BC pts were accrued. Sera from healthy volunteers (HV) were obtained to establish GP88 baseline. BC patient characteristics: Caucasian- 91, African American-92, Asian-6; median age, 51 (range 29- 86), stage I - 48, II - 52, III - 26, IV - 63. Results: Median serum GP88 level was 28.7 ng/ml (range 16.6–38.2) in HV, 40.7 ng/ml (range 6.4–100) in early stage (stage 1 -3) BC pts (p- value = 0.007) and 45.3 ng/ml (range 9.8 to 158.4) in stage 4 BC patients (p- value= 0.0007). Statistically significant increase in serum GP88 level was found in early stages as well as in metastatic disease when compared to HV. In addition, patients that were initially diagnosed with early stage disease but recurred showed a 5 to 10 fold increase in their GP88 serum levels. Conclusions: GP88 serum level is significantly higher in the sera of BC than HV subjects. Moreover, GP88 serum level increased in association with disease recurrence and progression. This study identifies GP88 as a measurable biomarker for disease progression not only at the tissue but also at the serum level. These results are also interesting since GP88 is also a therapeutic target of malignant progression of breast carcinoma. No significant financial relationships to disclose.

Elevated serum levels of transforming growth factor-α in breast cancer patients

1994 ◽  
Vol 79 (2) ◽  
pp. 157-160 ◽  
Author(s):  
Subhas Chakrabarty ◽  
Shuang Huang ◽  
Thomas L. Moskal ◽  
Herbert A. Fritsche
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cancer Patients ◽  
Transforming Growth Factor ◽  
Elevated Serum ◽  
Serum Levels ◽  
Breast Cancer Patients ◽  
Transforming Growth Factor Α ◽  
Factor Α

Circulating levels of the breast cancer growth factor GP88 in the serum of breast cancer (BC) patients

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20050-20050
Author(s):  
G. Serrero ◽  
K. Tkaczuk ◽  
N. Tait ◽  
O. Golubeva ◽  
H. Dai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Serum Level ◽  
Healthy Volunteers ◽  
Cancer Patients ◽  
Critical Role ◽  
Estrogen Therapy ◽  
Breast Adenocarcinoma ◽  
P Value ◽  
Breast Cancer Patients

20050 Background: The 88 kDa autocrine growth factor PC-Cell Derived Growth Factor (GP88) plays a critical role in breast tumorigenesis. GP88 expression was low in estrogen receptor positive cells, whereas in ER negative cells, it was constitutively overexpressed. Increased GP88 expression was associated with anti-estrogen therapy resistance in ER+ cells and Herceptin resistance in Her-2 overexpressing breast tumors. Antisense inhibition of GP88 expression in human breast adenocarcinoma lead to inhibition of tumor growth in vivo. Immunohistochemical studies have shown that GP88 was expressed in 80% of invasive ductal carcinomas in correlation with expression of poor prognosis markers whereas normal tissues and benign breast lesions were negative. Since GP88 is secreted by breast cancer cells, we examined whether GP88 was found in the circulation at an elevated level in the sera of breast cancer patients when compared to healthy individuals. Methods: A blood sampling study was conducted to determine the serum level of GP88 in healthy volunteers (HV) and breast cancer patients (BC pts). Ten ml of blood was drawn every three months to obtain serum. GP88 serum concentration was determined in triplicate by quantitative enzyme immunoassay using human GP88 as standard. 126 BC pts were accrued. . In addition, sera from 53 healthy volunteers were obtained to establish a GP88 baseline in HV. BC pts characteristics: race: Caucasian- 61, African American-60, Asian-5; median age: 52.5 (range 26–84), stage I-32, II-34, III-18, IV-42. Results: Circulating GP88 was measurable in the serum. Median level of GP88 was 32.8 ng/ml (range 15.3–42.8) in HV and 43.8 ng/ml (range 15.4–158.4) in BC pts, (p-value = 0.0007). Conclusions: GP88 is measurable in the sera of HV and BC pts. Comparison between the two groups indicates that GP88 level is significantly higher in the sera of BC pts. These studies are important since it identifies GP88 as a measurable biomarker that is also a therapeutic target of malignant transformation or malignant progression of breast carcinoma (BC). Future studies will examine the correlation of GP88 level with BC prognostic factors. Correlation between the serum level of GP88 and therapeutic response to systemic therapy in breast cancer patients will also be assessed. [Table: see text]

scholarly journals Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ina Mathilde Kjær ◽  
Dorte Aalund Olsen ◽  
Ivan Brandslund ◽  
Troels Bechmann ◽  
Erik Hugger Jakobsen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cancer Patients ◽  
Early Stage ◽  
Serum Levels ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Egfr Ligands ◽  
Epidermal Growth

Abstract Epidermal growth factor receptor (EGFR) and its ligands are involved in cancer pathogenesis. The emerging role of treatments co-targeting the EGFR system in breast cancer has increased the need to identify companion biomarkers. The aim of this study is to investigate whether pretreatment serum levels of EGFR and EGFR ligands in early-stage breast cancer patients might provide prognostic information as a stepping stone for further investigation. The study, which included 311 early-stage breast cancer patients, investigated associations between preoperative serum levels of EGFR and EGFR ligands (epidermal growth factor, heparin-binding epidermal growth factor (HBEGF), amphiregulin, transforming growth factor-α and betacellulin) and survival. Cutoffs were determined using Youden’s method, and overall survival (OS) and invasive disease-free survival (IDFS) were evaluated using Cox regression. Preoperative S-EGFR < 60.3 ng/mL was associated with shorter OS and IDFS in both univariate analyses and when adjusting for standard prognostic factors (p < 0.05). Preoperative S-HBEGF < 21.4 pg/mL was associated with shorter OS in both univariate and multivariate analyses, whereas association with shorter IDFS could only be demonstrated in the univariate analysis. In conclusion, our study demonstrated shorter survival in early-stage breast cancer patients who had low pretreatment levels of either S-EGFR or S-HBEGF.

N-acetylglucosaminidase, myeloperoxidase and vascular endothelial growth factor serum levels in breast cancer patients

2014 ◽  
Vol 68 (2) ◽  
pp. 185-189 ◽  
Author(s):  
Bertha Andrade Coelho ◽  
Andrezza Vilaça Belo ◽  
Sílvia Passos Andrade ◽  
Washington Cançado Amorim ◽  
Gilberto Uemura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Breast Cancer Patients ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document